Day 2 Recap: AAD 2025

Author(s):

Kaitlyn Bader, Assistant Managing Editor

Key Takeaways

Bimzelx demonstrated rapid, durable responses and long-term safety in psoriasis patients over five years.
Tapinarof cream 1% effectively maintained low disease activity in atopic dermatitis for an average of 79.8 days post-treatment.
Ruxolitinib cream showed promising results in treating prurigo nodularis, marking a significant development in topical treatments.
Dupilumab was found effective for bullous pemphigoid, offering a new therapeutic option for this condition.
An AI tool was developed to simplify dermatological documentation, allowing more focus on patient care.

Catch up on coverage from the second day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Alexandra P Charrow, MD, FAAD, Discusses Complex Medical Dermatology, HS at AAD Annual Meeting

Charrow shares insights in complex dermatology and her work in HS at the annual meeting.

Jeff Stark, MD: Reviewing UCB's Abstracts Across HS, PsO, PsA, and More

At AAD 2025, UCB will present 5-year data for Bimzelx in psoriasis, highlighting rapid, durable responses and long-term safety for patients.

Tapinarof Extends Symptom-Free Periods in Patients with AD

The ADORING 3 study demonstrated that tapinarof cream 1% maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

Insights From the ADORING 3 Study and Tapinarof’s Treatment-Free Periods in AD

Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream data presented at AAD 2025.

Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis

Shawn Kwatra, MD, FAAD, reviews his late-breaking data presentation at AAD on the first original studies of a topical cream for prurigo nodularis.

Adewole Adamson, MD, MPP: Addressing Melanoma Diagnosis and Overdiagnosis

Adamson highlighted melanoma's rising incidence and the growing concerns of overdiagnosis at AAD 2025.

Late Breaking: Data From Pivotal Trial Reports Dupilumab Effective for Bullous Pemphigoid

Late breaking data points to positive data for dupilumab for bullous pemphigoid.

Dermatologist Creates AI Tool to Make Documentation Easier

Michael Sherling, MD, MBA, leverages AI to simplify administrative tasks and focus on patient care.

Late-Breaking Data: Super Responders With Delgocitinib for CHE

April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib.

Stay tuned for more expert insights, clinical research, and late-breaking data from AAD 2025.